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Abstract
The pathogenesis of chronic lymphocytic leukemia (CLL) has been linked to constitutive NF-κB 
activation but the underlying mechanisms are poorly understood. Here we show that alternative 
splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of 
CD5+ B cells through sustained canonical NF-κB signaling. Reinforced canonical NF-κB activity 
leads to the development of B1 cell-associated tumor formation in aging mice by promoting 
survival and proliferation of CD5+ B cells, highly reminiscent of human B-CLL. We show that a 
substantial number of CLL patient samples express sCYLD, strongly implicating a role for it in 
human B-CLL. We propose that our new CLL-like mouse model represents an appropriate tool for 
studying ubiquitination-driven canonical NF-κB activation in CLL. Thus, inhibition of alternative 
splicing of this negative regulator is essential for preventing NF-κB-driven clonal CD5+ B-cell 
expansion and ultimately CLL-like disease.
